PT1381346E - Composições farmacêuticas com formoterol - Google Patents

Composições farmacêuticas com formoterol Download PDF

Info

Publication number
PT1381346E
PT1381346E PT2709742T PT02709742T PT1381346E PT 1381346 E PT1381346 E PT 1381346E PT 2709742 T PT2709742 T PT 2709742T PT 02709742 T PT02709742 T PT 02709742T PT 1381346 E PT1381346 E PT 1381346E
Authority
PT
Portugal
Prior art keywords
pharmaceutical composition
sodium
acid
buffer
composition
Prior art date
Application number
PT2709742T
Other languages
English (en)
Portuguese (pt)
Inventor
Partha S Banerjee
Stephen Pham
Imtiaz A Chaudry
Original Assignee
Mylan Specialty L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26962700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1381346(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mylan Specialty L P filed Critical Mylan Specialty L P
Publication of PT1381346E publication Critical patent/PT1381346E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT2709742T 2001-04-17 2002-02-28 Composições farmacêuticas com formoterol PT1381346E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28460601P 2001-04-17 2001-04-17
US09/887,281 US6667344B2 (en) 2001-04-17 2001-06-22 Bronchodilating compositions and methods

Publications (1)

Publication Number Publication Date
PT1381346E true PT1381346E (pt) 2016-02-04

Family

ID=26962700

Family Applications (1)

Application Number Title Priority Date Filing Date
PT2709742T PT1381346E (pt) 2001-04-17 2002-02-28 Composições farmacêuticas com formoterol

Country Status (9)

Country Link
US (2) US6667344B2 (https=)
EP (1) EP1381346B1 (https=)
JP (4) JP2004532217A (https=)
AU (1) AU2002244211B2 (https=)
CA (1) CA2438544C (https=)
ES (1) ES2554476T3 (https=)
PT (1) PT1381346E (https=)
SI (1) SI1381346T1 (https=)
WO (1) WO2002083079A2 (https=)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2002026223A2 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20020187099A1 (en) * 2001-05-16 2002-12-12 Rajesh Manchanda Stabilization of radionuclide-containing compositions
EP1397134A2 (en) * 2001-05-25 2004-03-17 Boehringer Ingelheim Pharma GmbH & Co.KG Combination of a dopamine d2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
WO2004027824A2 (en) * 2002-09-18 2004-04-01 Infineon Technologies Ag Nitride and polysilicon interface with titanium layer
US20040110845A1 (en) * 2002-12-06 2004-06-10 Ramana Malladi Stabilized albuterol compositions and method of preparation thereof
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
WO2004082557A2 (en) * 2003-03-15 2004-09-30 Brin Tech International Limited Package for and formulation of medicaments
SE0301260D0 (sv) * 2003-04-29 2003-04-29 Astrazeneca Ab Novel equipment
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ES2294543T3 (es) * 2003-07-09 2008-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050042176A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a steroid
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
EP1651224B1 (en) * 2003-07-31 2011-10-05 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005040257A1 (en) 2003-10-21 2005-05-06 E.I. Dupont De Nemours And Company Ethylene copolymer modified oriented polyester films, tapes, fibers and nonwoven textiles
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
RU2438660C2 (ru) * 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
EP1713473B1 (en) * 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
WO2005074982A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
JP2007531743A (ja) * 2004-04-05 2007-11-08 セプラコア インコーポレーテッド 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
JP2008502699A (ja) * 2004-06-14 2008-01-31 セプラコール・インコーポレイテッド 肺疾患治療方法、及びそのための組成物
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
EA200700600A1 (ru) * 2004-09-09 2008-02-28 Сипла Лимитед Фармацевтическая композиция, содержащая изомер бета-миметического агента и антихолинергический агент
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
ES2570332T3 (es) * 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
EP2402001A1 (en) * 2005-05-18 2012-01-04 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
CN101198313A (zh) * 2005-08-01 2008-06-11 奇斯药制品公司 通过喷雾施用的包含长效β2－激动剂的药物制剂
WO2007034325A1 (en) * 2005-09-21 2007-03-29 Pfizer Limited Carboxamide derivatives as muscarinic receptor antagonists
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
NZ591969A (en) 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
JP2009537569A (ja) * 2006-05-18 2009-10-29 ティカ レーケメデル アーベー 気管支拡張を誘発するためのβ２アゴニストの送達のための方法およびそれを使用するための製剤
AU2007267523B2 (en) * 2006-05-26 2012-02-09 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
EP1925296A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein neues Anticholinergikum
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
CN102131827A (zh) * 2007-12-13 2011-07-20 葛兰素集团有限公司 用于肺部传递给药的组合物
WO2009086470A2 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
GB2468073B (en) * 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CA2754691C (en) 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN101544386B (zh) * 2009-04-29 2011-01-05 余荣华 一种生产硝酸钾并联产氯化铵和硝酸铵的方法
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
UA113832C2 (xx) 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
IN2012DN05192A (https=) * 2010-01-21 2015-10-23 Aprea Ab
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
CN107224427A (zh) * 2013-07-01 2017-10-03 成都苑东生物制药股份有限公司 一种格隆溴铵注射液组合物及其制备方法
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
CN107362140A (zh) * 2016-05-11 2017-11-21 广东东阳光药业有限公司 喷雾剂以及喷雾组件
WO2018069887A1 (en) * 2016-10-14 2018-04-19 Glenmark Specialty S.A. Nebulizable compositions of tiotropium and formoterol
CN108853011B (zh) * 2018-06-13 2021-01-29 北京华润高科天然药物有限公司 一种葡萄糖酸钙-l-乳酸钙口服液及其制备方法
EP3893862B1 (en) * 2018-12-14 2023-11-22 National Taiwan University A stable cardioplegic solution for cardiac surgery
CN112870172B (zh) * 2019-11-29 2022-09-13 北京福元医药股份有限公司 一种孟鲁司特钠药物制剂
US20210275449A1 (en) * 2020-03-01 2021-09-09 Cai Gu Huang Inhalable Formulation of a Solution Containing Glycopyrronium Bromide
CN112326808A (zh) * 2020-09-24 2021-02-05 南京斯泰尔医药科技有限公司 一种测定注射液中焦亚硫酸钠含量的方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2305092A1 (de) 1972-02-05 1973-08-16 Yamanouchi Pharma Co Ltd Alpha-aminomethylbenzylalkoholderivate
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (https=) 1972-05-19 1975-08-18 Bofors Ab
JPS56138200A (en) 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
US4578221A (en) 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8825892D0 (en) 1988-11-04 1988-12-07 Fisons Plc Pharmaceutical composition
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
AU8739091A (en) 1990-09-18 1992-04-15 Thomas James Frederick Digital servo control system for use in disk drives
US5919435A (en) 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5785952A (en) 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
DK0616524T3 (da) 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
ES2172510T3 (es) 1991-12-18 2002-10-01 Astrazeneca Ab Nueva combinacion de formoterol y budesonida.
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US5525623A (en) 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US5602110A (en) 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
GB9419536D0 (en) 1994-09-28 1994-11-16 Glaxo Inc Medicaments
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5980949A (en) 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5647347A (en) 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
DE19541689A1 (de) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DZ1965A1 (fr) 1995-02-06 2002-07-17 Astra Ab Composition pharmaceutique nouvelle.
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
MX9707862A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida para el propionato de fluticasona.
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US6041777A (en) 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
US5733526A (en) 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
US5753218A (en) 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US6077543A (en) 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
AU718967B2 (en) 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
DK0969816T3 (da) 1997-03-20 2005-03-14 Schering Corp Fremstilling af pulveragglomerater
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
WO1999000134A1 (en) 1997-06-27 1999-01-07 Astra Aktiebolag (Publ) New combination of antiasthma medicaments
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ATE215820T1 (de) * 1997-10-08 2002-04-15 Sepracor Inc Dosierungsform zur verabreichung von aerosolen
US5972327A (en) 1997-10-22 1999-10-26 Lin; Matthew M. Method of treating allergic rhinitis by delivering medication via the nasal vestibules
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
AU2505599A (en) 1998-02-10 1999-08-30 Cangene Corporation Method for the prevention and treatment of a type i hypersensitivity disorder
US5972920A (en) 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9806462D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
US5993782A (en) 1998-04-28 1999-11-30 Gardner; Conrad O. Therapeutic method for reversing hyposmia in a human patient
DE29923847U1 (de) 1998-05-27 2001-04-12 Euroceltique S.A., Luxemburg/Luxembourg Präparate zur Anwendung von entzündungshemmenden, insbesondere antiseptischen Wirkstoffen und/oder die Wundheilung fördernden Wirkstoffen in den unteren Atemwegen
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US5965622A (en) 1998-06-23 1999-10-12 Sepracor Inc. Desformoterol and process for its preparation
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
JP4570251B2 (ja) 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
CN1150890C (zh) 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
US6112924A (en) 1998-09-10 2000-09-05 Bcb Usa, Inc. Container with base having cylindrical legs with circular feet
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
HRP20010255A2 (en) * 1998-10-17 2002-04-30 Boehringer Ingelheim Pharma Storable active substance concentrate with formoterol
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
IT1303692B1 (it) 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
AU756852B2 (en) 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
AU7026800A (en) 1999-09-11 2001-04-17 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
DE19947235A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9903995D0 (sv) 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
AU2001252350A1 (en) 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
ES2239203T3 (es) 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods

Also Published As

Publication number Publication date
EP1381346A2 (en) 2004-01-21
ES2554476T3 (es) 2015-12-21
WO2002083079A9 (en) 2003-04-10
US20020151598A1 (en) 2002-10-17
CA2438544C (en) 2010-11-09
JP6214925B2 (ja) 2017-10-18
WO2002083079A2 (en) 2002-10-24
JP2013155208A (ja) 2013-08-15
US20020151597A1 (en) 2002-10-17
JP2009046490A (ja) 2009-03-05
WO2002083079A3 (en) 2003-02-13
US6814953B2 (en) 2004-11-09
JP2015178506A (ja) 2015-10-08
SI1381346T1 (sl) 2016-03-31
US6667344B2 (en) 2003-12-23
CA2438544A1 (en) 2002-10-24
EP1381346B1 (en) 2015-11-18
AU2002244211B2 (en) 2007-07-05
JP2004532217A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
US6814953B2 (en) Bronchodilating compositions and methods
US7465756B2 (en) Bronchodilating beta-agonist compositions and methods
EP1385494B1 (en) Compositions containing formoterol and a steroid for delivery into the lungs
AU2002244211A1 (en) Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization
AU2002250199A1 (en) Formoterol/steroid bronchodilating compositions and methods of use thereof
HK1061523B (en) Compositions containing formoterol and a steroid for delivery into the lungs